JP2022542543A5 - - Google Patents
Info
- Publication number
- JP2022542543A5 JP2022542543A5 JP2022502899A JP2022502899A JP2022542543A5 JP 2022542543 A5 JP2022542543 A5 JP 2022542543A5 JP 2022502899 A JP2022502899 A JP 2022502899A JP 2022502899 A JP2022502899 A JP 2022502899A JP 2022542543 A5 JP2022542543 A5 JP 2022542543A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- sequence
- cdr2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025015341A JP7894963B2 (ja) | 2019-07-17 | 2025-01-31 | 抗dll3キメラ抗原受容体及びその使用 |
| JP2025156914A JP2026001061A (ja) | 2019-07-17 | 2025-09-22 | 抗dll3キメラ抗原受容体及びその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019096360 | 2019-07-17 | ||
| CNPCT/CN2019/096360 | 2019-07-17 | ||
| CN2020090587 | 2020-05-15 | ||
| CNPCT/CN2020/090587 | 2020-05-15 | ||
| PCT/CN2020/102717 WO2021008610A1 (en) | 2019-07-17 | 2020-07-17 | Anti-dll3 chimeric antigen receptors and uses thereof |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025015341A Division JP7894963B2 (ja) | 2019-07-17 | 2025-01-31 | 抗dll3キメラ抗原受容体及びその使用 |
| JP2025156914A Division JP2026001061A (ja) | 2019-07-17 | 2025-09-22 | 抗dll3キメラ抗原受容体及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022542543A JP2022542543A (ja) | 2022-10-05 |
| JP2022542543A5 true JP2022542543A5 (cg-RX-API-DMAC7.html) | 2023-07-21 |
| JP7748933B2 JP7748933B2 (ja) | 2025-10-03 |
Family
ID=74210175
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022502899A Active JP7748933B2 (ja) | 2019-07-17 | 2020-07-17 | 抗dll3キメラ抗原受容体及びその使用 |
| JP2025015341A Active JP7894963B2 (ja) | 2019-07-17 | 2025-01-31 | 抗dll3キメラ抗原受容体及びその使用 |
| JP2025156914A Pending JP2026001061A (ja) | 2019-07-17 | 2025-09-22 | 抗dll3キメラ抗原受容体及びその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025015341A Active JP7894963B2 (ja) | 2019-07-17 | 2025-01-31 | 抗dll3キメラ抗原受容体及びその使用 |
| JP2025156914A Pending JP2026001061A (ja) | 2019-07-17 | 2025-09-22 | 抗dll3キメラ抗原受容体及びその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12421292B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4527466A3 (cg-RX-API-DMAC7.html) |
| JP (3) | JP7748933B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220035367A (cg-RX-API-DMAC7.html) |
| CN (4) | CN118420777A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020314509A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3146019A1 (cg-RX-API-DMAC7.html) |
| TW (2) | TW202535924A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021008610A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021180215A1 (en) | 2020-03-12 | 2021-09-16 | Nanjing Legend Biotech Co., Ltd. | Glypican-2-binding moieties, chimeric antigen receptors and uses thereof |
| US20240150456A1 (en) * | 2021-04-02 | 2024-05-09 | Nanjing Legend Biotech Co., Ltd. | Engineered immune cells and uses thereof |
| CA3230627A1 (en) * | 2021-09-02 | 2023-03-09 | Memorial Sloan-Kettering Cancer Center | Antigen recognizing receptors targeting dll3 and uses thereof |
| EP4499680A1 (en) * | 2022-03-29 | 2025-02-05 | Allogene Therapeutics, Inc. | Chimeric switch receptors for the conversion of immunesuppressive signals to costimulatory signals |
| WO2024006281A2 (en) * | 2022-06-28 | 2024-01-04 | Carisma Therapeutics Inc. | Switch receptors and modified immune cells |
| JP2025525496A (ja) * | 2022-07-08 | 2025-08-05 | イマジナブ・インコーポレーテッド | Dll3抗原結合構築物 |
| US20260061051A1 (en) * | 2022-08-26 | 2026-03-05 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for delta-like ligand 3 (dll3) |
| CN115820698B (zh) * | 2022-11-22 | 2025-01-21 | 浙江康佰裕生物科技有限公司 | 含有嵌合抗原受体和嵌合转换开关受体编码基因的融合基因及其应用 |
| CN116004547B (zh) * | 2023-03-06 | 2025-04-25 | 浙江康佰裕生物科技有限公司 | 一种辐照car-t细胞及其制备方法与应用 |
| CN121152872A (zh) * | 2023-05-10 | 2025-12-16 | 南京传奇生物科技有限公司 | 嵌合抗原受体及其使用方法 |
| KR20260079181A (ko) * | 2023-09-26 | 2026-06-01 | 레전드 바이오테크 유에스에이, 인크. | Dll3 결합 모이어티 및 이의 용도 |
| CN122094981A (zh) | 2023-10-16 | 2026-05-26 | 上海先博生物科技有限公司 | 一种靶向δ样配体3的CAR及应用 |
| WO2025201493A1 (zh) * | 2024-03-29 | 2025-10-02 | 诺纳生物(苏州)有限公司 | Dll3结合分子及其用途 |
| WO2025212519A1 (en) * | 2024-04-01 | 2025-10-09 | Moonlight Bio, Inc. | Dll3 binding proteins and uses thereof |
| WO2025240849A1 (en) * | 2024-05-16 | 2025-11-20 | The Brigham And Women's Hospital, Inc. | Trem2 chimeric antigen receptors and uses thereof |
| WO2026008059A1 (en) * | 2024-07-04 | 2026-01-08 | Nanjing Legend Biotech Co., Ltd. | Anti-dll3 constructs and uses thereof |
| WO2026052061A1 (en) * | 2024-09-05 | 2026-03-12 | Nanjing Legend Biotech Co., Ltd. | Adoptive cell compositions |
| WO2026051938A1 (en) * | 2024-09-05 | 2026-03-12 | Therorna Shanghai Co., Ltd. | Circular rna encoding chimeric antigen receptors targeting dll3 and the use thereof |
| CN119708238B (zh) * | 2025-02-27 | 2025-07-04 | 昕传生物科技(北京)有限公司 | 靶向dll3的抗体、嵌合抗原受体及其应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| WO1999029888A1 (en) | 1997-12-05 | 1999-06-17 | The Scripps Research Institute | Humanization of murine antibody |
| MA41613A (fr) | 2015-02-23 | 2018-01-02 | Abbvie Stemcentrx Llc | Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs |
| TWI793062B (zh) * | 2015-07-31 | 2023-02-21 | 德商安美基研究(慕尼黑)公司 | Dll3及cd3抗體構築體 |
| CN105153315B (zh) * | 2015-10-09 | 2019-04-02 | 重庆精准生物技术有限公司 | 免疫抑制受体联合肿瘤抗原嵌合受体及其应用 |
| CA3034691A1 (en) | 2016-08-30 | 2018-03-08 | Memorial Sloan Kettering Cancer Center | Immune cell compositions and methods of use for treating viral and other infections |
| CN108276493B (zh) * | 2016-12-30 | 2023-11-14 | 南京传奇生物科技有限公司 | 一种嵌合抗原受体及其应用 |
| JP2020517263A (ja) | 2017-04-19 | 2020-06-18 | ユニバーシティ オブ サザン カリフォルニア | がんを治療するための組成物及び方法 |
| BR112020005938A2 (pt) | 2017-09-27 | 2020-11-17 | University Of Southern California | célula imune ou população de células imunes da mesma, célula efetora imune ou célula-tronco, célula que apresenta antígeno, polinucleotídeo recombinante, vetor, composição que compreende uma célula imune efetora ou uma célula-tronco, métodos para produzir uma célula efetora imune que expressa receptor imune de ocorrência não natural, para gerar uma população de células manipuladas por rna, para fornecer imunidade antidoença em um indivíduo, para tratar ou prevenir uma doença associada à expressão de um antígeno, e, uso |
| US20220025037A1 (en) | 2018-04-03 | 2022-01-27 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting dll3, and use thereof |
| CR20200539A (es) | 2018-04-10 | 2021-07-01 | Kite Pharma Inc | Receptores quiméricos de dll3 y métodos para su uso |
-
2020
- 2020-07-17 EP EP25154055.5A patent/EP4527466A3/en active Pending
- 2020-07-17 TW TW114114222A patent/TW202535924A/zh unknown
- 2020-07-17 AU AU2020314509A patent/AU2020314509A1/en active Pending
- 2020-07-17 TW TW109124309A patent/TWI883026B/zh active
- 2020-07-17 KR KR1020227000346A patent/KR20220035367A/ko active Pending
- 2020-07-17 CA CA3146019A patent/CA3146019A1/en active Pending
- 2020-07-17 CN CN202410399472.2A patent/CN118420777A/zh active Pending
- 2020-07-17 CN CN202080047990.8A patent/CN114072427B/zh active Active
- 2020-07-17 US US17/618,642 patent/US12421292B2/en active Active
- 2020-07-17 EP EP20840073.9A patent/EP3999550A4/en active Pending
- 2020-07-17 CN CN202311129421.XA patent/CN117106099A/zh active Pending
- 2020-07-17 JP JP2022502899A patent/JP7748933B2/ja active Active
- 2020-07-17 WO PCT/CN2020/102717 patent/WO2021008610A1/en not_active Ceased
- 2020-07-17 CN CN202410399887.XA patent/CN118496374A/zh active Pending
-
2025
- 2025-01-31 JP JP2025015341A patent/JP7894963B2/ja active Active
- 2025-08-22 US US19/308,077 patent/US20260078166A1/en active Pending
- 2025-09-22 JP JP2025156914A patent/JP2026001061A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20260078166A1 (en) | Anti-dll3 chimeric antigen receptors and uses thereof | |
| JP6669722B2 (ja) | Cd3結合ドメイン | |
| JP2025065142A5 (cg-RX-API-DMAC7.html) | ||
| JP2022518925A5 (cg-RX-API-DMAC7.html) | ||
| JP2024125370A (ja) | クローディン18.2結合部分およびその利用 | |
| JP2017527275A5 (cg-RX-API-DMAC7.html) | ||
| JP2015527070A5 (cg-RX-API-DMAC7.html) | ||
| CN111378044B (zh) | 抗体融合蛋白、制备方法及其应用 | |
| JP2018538277A5 (cg-RX-API-DMAC7.html) | ||
| JP2024508672A (ja) | 新規抗cd24抗体 | |
| US11945878B2 (en) | Switch molecule and switchable chimeric antigen receptor | |
| JP2024504162A5 (cg-RX-API-DMAC7.html) | ||
| JP2023554467A5 (cg-RX-API-DMAC7.html) | ||
| JP7730432B2 (ja) | がん治療におけるpd-1シグナル阻害剤との組み合わせによる抗cldn4-抗cd137二重特異性抗体の使用 | |
| JP2024539079A5 (cg-RX-API-DMAC7.html) | ||
| JP2023549441A5 (cg-RX-API-DMAC7.html) | ||
| JP2023535485A (ja) | 抗cd22シングルドメイン抗体および治療用コンストラクト | |
| JP2025087939A (ja) | がん治療におけるpd-1シグナル阻害剤との組み合わせによる抗tspan8-抗cd3二重特異性抗体の使用 | |
| HK40110781A (en) | Anti-dll3 chimeric antigen receptors and uses thereof | |
| HK40110214A (en) | Anti-dll3 chimeric antigen receptors and uses thereof | |
| HK40098926A (en) | Anti-dll3 chimeric antigen receptors and uses thereof | |
| HK40065826A (en) | Anti-dll3 chimeric antigen receptors and uses thereof | |
| HK40065826B (en) | Anti-dll3 chimeric antigen receptors and uses thereof |